FeRx evaluates drug delivery technology for cancer:
This article was originally published in Clinica
Executive Summary
FeRx is receiving a grant from the US National Cancer Institute of the National Institutes of Health to assess the effectiveness of its microparticle drug delivery system for treating pancreatic cancer. The San Diego, California firm will evaluate the use of its MagneTarg technology for the targeted delivery of the drug gemcitabine. The microparticles are made of metallic iron and activated carbon and are drawn to the tumour site using a magnetic field.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.